未经证实:2019年冠状病毒病(COVID-19)大流行突显了一个事实,即几乎没有有效的抗病毒药物可以治疗严重的急性呼吸道综合症冠状病毒2(SARS-CoV-2)感染。尽管疫苗的最新发展是一个极其重要的突破,目前尚不清楚这种疫苗的寿命有多长。因此,开发新试剂仍然是重要的目标。
未经评估:鉴于COVID-19的多方面病理,组合制剂可能提供有效的治疗。BEN815,一种由番石榴叶(Psidiumguajava)提取物组成的天然营养品,绿茶叶(山茶),和玫瑰花瓣(罗莎杂交),以前证明对过敏性鼻炎有治疗作用。我们调查了BEN815是否具有抗炎作用,抗病毒和抗氧化活性,因为这些作用的组合可能对COVID-19的治疗有用。
未经证实:我们研究了BEN815及其主要活性成分槲皮素和表没食子儿茶素没食子酸酯(EGCG)在脂多糖(LPS)诱导的RAW264.7细胞和LPS攻击的内毒素血症小鼠模型中的抗炎作用。我们还评估了抗氧化活性,和抗病毒作用的BEN815,槲皮素,和EGCG在SARS-CoV-2感染的Vero细胞中。
未经鉴定:使用HPLC测定和定量BEN815中的主要活性成分。ELISA法测定LPS诱导的促炎细胞因子白细胞介素(IL)-6和肿瘤坏死因子(TNF)-α水平的变化。使用蛋白质印迹分析了环氧合酶(COX)-2和诱导型一氧化氮合酶(iNOS)表达水平的变化。使用DPPH和ABTS测定进行抗氧化剂测定。通过免疫荧光染色测量SARS-CoV-2复制。
未经证实:BEN815显著抑制LPS诱导的RAW264.7细胞中IL-6和TNF-α以及COX-2和iNOS的诱导。此外,BEN815保护小鼠免受LPS攻击的内毒素休克。两种主要成分BEN815,槲皮素和EGCG,降低了LPS诱导的RAW264.7细胞中IL-6和TNF-α以及COX-2和iNOS合酶的诱导。BEN815,槲皮素,和EGCG也被发现具有抗氧化作用。重要的是,BEN815和EGCG可以抑制SARS-CoV-2在Vero细胞中的复制。
未经批准:BEN815是一种抗炎药,抗病毒,以及可用于预防和改善炎症相关疾病的天然抗氧化剂,COVID-19。
UNASSIGNED: The corona virus disease 2019 (COVID-19) pandemic has highlighted the fact that there are few effective antiviral agents for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Although the very recent development of vaccines is an extremely important breakthrough, it remains unclear how long-lived such vaccines will be. The development of new agents therefore remains an important goal.
UNASSIGNED: Given the multifaceted pathology of COVID-19, a combinatorial formulation may provide an effective treatment. BEN815, a natural nutraceutical composed of extracts from guava leaves (Psidium guajava), green tea leaves (Camellia sinensis), and rose petals (Rosa hybrida), had previously shown to have a therapeutic effect on allergic rhinitis. We investigated whether BEN815 possesses anti-inflammatory, antiviral and antioxidant activities, since the combination of these effects could be useful for the treatment of COVID-19.
UNASSIGNED: We examined the anti-inflammatory effects of BEN815 and its principal active components quercetin and epigallocatechin gallate (EGCG) in lipopolysaccharide (LPS)-induced RAW264.7 cells and in an LPS-challenged mouse model of endotoxemia. We also assessed the antioxidant activity, and antiviral effect of BEN815, quercetin, and EGCG in SARS-CoV-2-infected Vero cells.
UNASSIGNED: The principal active ingredients in BEN815 were determined and quantified using HPLC. Changes in the levels of LPS-induced pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α were measured by ELISA. Changes in the expression levels of cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) were analyzed using western blotting. Antioxidant assay was performed using DPPH and ABTS assay. SARS-CoV-2 replication was measured by immunofluorescence staining.
UNASSIGNED: BEN815 significantly suppressed the induction of IL-6 and TNF-α as well as COX-2 and iNOS in LPS-induced RAW264.7 cells. In addition, BEN815 protected against LPS-challenged endotoxic shock in mice. Two major constituents of BEN815, quercetin and EGCG, reduced the induction of IL-6 and TNF-α as well as COX-2 and iNOS synthase in LPS-induced RAW264.7 cells. BEN815, quercetin, and EGCG were also found to have antioxidant effects. Importantly, BEN815 and EGCG could inhibit SARS-CoV-2 replications in Vero cells.
UNASSIGNED: BEN815 is an anti-inflammatory, antiviral, and antioxidant natural agent that can be used to prevent and improve inflammation-related diseases, COVID-19.